Last reviewed · How we verify
NCT02948036
A Closed-loop Assessment and Treatment Platform for Unipolar Depression and Anxiety
NA trial testing Mobile-device, plasticity-based adaptive cognitive treatment in Major Depressive Disorder in 31 participants. Completed in 11 May 2023.
11 May 2023
Quick facts
| Lead sponsor | Posit Science Corporation |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 31 |
| Start date | 1 October 2017 |
| Primary completion | 11 May 2023 |
| Estimated completion | 11 May 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Mobile-device, plasticity-based adaptive cognitive treatment
Conditions studied
- Major Depressive Disorder — all drugs for Major Depressive Disorder →
Sponsor
Posit Science Corporation — full company profile →
Who can join
Adults 18 to 60, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Specific Aim 1: Finalize development of the closed-loop strategy in the MMT application. Specific Aim 2: Evaluate the acceptability and feasibility of the MMT application with the target population to prepare for a large-scale efficacy trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02948036
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Major Depressive Disorder
Currently open trials in the same condition.
- NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
- NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
- NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting
Other Posit Science Corporation trials
Trials by the same sponsor.
- NCT07243600 — Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impai · NA · not yet recruiting
- NCT06589024 — Remote STATE Training for Insomnia in Older Adults · NA · active not recruiting
- NCT05599490 — Brain Enhancement Training Towards Elders Resilience to Aging, Phase IIB · NA · completed
- NCT05529706 — Community-based Brain Health Program to Address Dementia Risk · NA · completed
- NCT05022589 — Remote Digital Health Intervention to Improve Balance and Reduce Fall Risk · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02948036 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Posit Science Corporation
- Last refreshed: 5 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02948036.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing